BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 18502338)

  • 1. Management of medullary thyroid carcinoma.
    Jiménez C; Hu MI; Gagel RF
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
    Moore SW; Appfelstaedt J; Zaahl MG
    J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The treatment of medullary thyroid cancer].
    Fujita T; Fujimori M
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1627-31. PubMed ID: 19838021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New presentation of familial medullary thyroid carcinoma in 87-year-old patient with high-risk RET proto-oncogene codon 620 mutation.
    Jaggard MK; MacRae C; Ifeacho S; Robinson S; Tolley NS
    J Laryngol Otol; 2009 Jul; 123(7):796-800. PubMed ID: 18771606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
    Fitze G; Saeger HD; Roesner D; Schackert HK
    Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular advances in medullary thyroid cancer diagnostics.
    Hubner RA; Houlston RS
    Clin Chim Acta; 2006 Aug; 370(1-2):2-8. PubMed ID: 16519882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thyroid carcinomas and Hirschsprung's disease--10-year experience with molecular genetic testing of the RET proto-oncogene].
    Bendlová B; Dvoráková S; Václavíková E; Sýkorová V; Vlcek P; Skába R
    Vnitr Lek; 2006 Oct; 52(10):926-34. PubMed ID: 17063805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report.
    Menon MM; Simha MR
    Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.
    Cerrato A; De Falco V; Santoro M
    J Mol Endocrinol; 2009 Oct; 43(4):143-55. PubMed ID: 19383830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medullary carcinoma of the thyroid: diagnosis and therapy].
    Giuffrida D; Ferraù F; Bordonaro R; Mattina M; Priolo D; Aiello RA; Cordio S; Motta S; Failla G
    Clin Ter; 2000; 151(1):29-35. PubMed ID: 10822879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome.
    Abu-Amero KK; Alzahrani AS; Zou M; Shi Y
    Oncogene; 2006 Feb; 25(5):677-84. PubMed ID: 16205644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients.
    Guyétant S; Josselin N; Savagner F; Rohmer V; Michalak S; Saint-André JP
    Mod Pathol; 2003 Aug; 16(8):756-63. PubMed ID: 12920219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and management of medullary thyroid carcinoma.
    Massoll N; Mazzaferri EL
    Clin Lab Med; 2004 Mar; 24(1):49-83. PubMed ID: 15157557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medullary thyroid carcinoma.
    Leboulleux S; Baudin E; Travagli JP; Schlumberger M
    Clin Endocrinol (Oxf); 2004 Sep; 61(3):299-310. PubMed ID: 15355445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and surgical dilemmas in hereditary medullary thyroid carcinoma.
    Allen SM; Bodenner D; Suen JY; Richter GT
    Laryngoscope; 2009 Jul; 119(7):1303-11. PubMed ID: 19444888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
    Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
    Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
    van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
    Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
    Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B
    Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medullary thyroid cancer.
    You YN; Lakhani V; Wells SA; Moley JF
    Surg Oncol Clin N Am; 2006 Jul; 15(3):639-60. PubMed ID: 16882502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.